Lynn Porter, MD
Family Medicine · Roberstdale, ALNPI 1508874751
Payments from drug & device makers
Across 690 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- GSK$1K
- Lilly USA, LLC$979
- Bayer$758
- Pfizer$595
- plus $4K from 31 others
What the payments were for
- Food & beverage$11,202100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 153 | $2,070 |
| AstraZeneca | 55 | $1,337 |
| GSK | 70 | $1,015 |
| Lilly USA, LLC | 65 | $979 |
| Bayer | 41 | $758 |
| Pfizer | 42 | $595 |
| AbbVie(2 entities) | 32 | $547 |
| Amarin Pharma, Inc. | 26 | $473 |
| Amgen | 30 | $447 |
| Johnson & Johnson | 27 | $432 |
| Merck | 24 | $341 |
| Novartis | 19 | $302 |
| Otsuka America Pharmaceutical, Inc. | 12 | $281 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $252 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $123 |
| Sanofi-aventis U.S. LLC | 7 | $121 |
| Xeris Pharmaceuticals, Inc. | 5 | $109 |
| Lundbeck LLC | 6 | $105 |
| Biohaven Pharmaceuticals, Inc. | 5 | $95 |
| Exact Sciences | 5 | $85 |
| Teva Pharmaceuticals USA, Inc. | 5 | $79 |
| Esperion Therapeutics, Inc. | 5 | $75 |
| Boehringer Ingelheim | 5 | $71 |
| Mylan Specialty L.p. | 4 | $69 |
| Radius Health, Inc. | 3 | $56 |
| Upsher-smith Laboratories LLC | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 3 | $50 |
| Paratek Pharmaceuticals, Inc. | 3 | $47 |
| Astellas Pharma US Inc | 3 | $42 |
| Insulet Corporation | 2 | $39 |
| Dexcom, Inc. | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Viiv Healthcare Company | 1 | $30 |
| GRT US Holding, Inc. | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,226 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 159 | $195,633 |
| EliquisApixaban | 138 | $104,009 |
| FarxigaDapagliflozin Propanediol | 119 | $95,992 |
| MounjaroTirzepatide | 60 | $80,148 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $60,795 |
| TrulicityDulaglutide | 19 | $38,808 |
| XareltoRivaroxaban | 45 | $37,822 |
| LinzessLinaclotide | 50 | $35,291 |
| VascepaIcosapent Ethyl | 52 | $25,385 |
| JardianceEmpagliflozin | 26 | $24,655 |
| JanuviaSitagliptin Phosphate | 12 | $18,012 |
| EntrestoSacubitril/Valsartan | 25 | $15,954 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $14,566 |
| RayaldeeCalcifediol | 11 | $13,167 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $12,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,070 | $195,633159 claims |
| Lilly USA, LLCMounjaro, Trulicity | $979 | $118,95679 claims |
| PfizerEliquis, Lyrica | $595 | $114,357150 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,337 | $107,326130 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy | $1,015 | $85,389115 claims |
| Johnson & JohnsonXarelto | $432 | $37,82245 claims |
| AbbVieLinzess | $547 | $35,29150 claims |
| Boehringer IngelheimJardiance | $71 | $24,65526 claims |
| MerckJanuvia | $341 | $18,01212 claims |
| NovartisEntresto | $302 | $15,95425 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $10,87131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Roberstdale
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.